Structure-guided design of a broadly cross-reactive multivalent group a streptococcal vaccine.

[1]  Jeremy C. Smith,et al.  Design of Broadly Cross-Reactive M Protein–Based Group A Streptococcal Vaccines , 2021, The Journal of Immunology.

[2]  M. Walker,et al.  Update on group A streptococcal vaccine development. , 2020, Current opinion in infectious diseases.

[3]  Jeremy C. Smith,et al.  Structure-based group A streptococcal vaccine design: Helical wheel homology predicts antibody cross-reactivity among streptococcal M protein–derived peptides , 2020, The Journal of Biological Chemistry.

[4]  J. Langley,et al.  Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study. , 2019, Vaccine.

[5]  A. Ralph,et al.  Concerns for efficacy of a 30-valent M-protein-based Streptococcus pyogenes vaccine in regions with high rates of rheumatic heart disease , 2019, PLoS neglected tropical diseases.

[6]  Jerome H. Kim,et al.  The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  T. Penfound,et al.  Development of an Opsonophagocytic Killing Assay Using HL-60 Cells for Detection of Functional Antibodies against Streptococcus pyogenes , 2018, mSphere.

[8]  Jeremy C. Smith,et al.  Structure-based design of broadly protective group a streptococcal M protein-based vaccines. , 2017, Vaccine.

[9]  Michael W Parker,et al.  A systematic and functional classification of Streptococcus pyogenes that serves as a new tool for molecular typing and vaccine development. , 2014, The Journal of infectious diseases.

[10]  J. Nataro,et al.  Potential coverage of a multivalent M protein-based group A streptococcal vaccine. , 2013, Vaccine.

[11]  T. Penfound,et al.  New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. , 2011, Vaccine.

[12]  T. Penfound,et al.  Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes. , 2010, Vaccine.

[13]  J. Carapetis,et al.  Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. , 2009, The Lancet. Infectious diseases.

[14]  J. Carapetis,et al.  The global burden of group A streptococcal diseases. , 2005, The Lancet. Infectious diseases.

[15]  J. Langley,et al.  Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  M. Reddish,et al.  Intranasal Immunization with Multivalent Group A Streptococcal Vaccines Protects Mice against Intranasal Challenge Infections , 2004, Infection and Immunity.

[17]  M. Delorenzi,et al.  An HMM model for coiled-coil domains and a comparison with PSSM-based predictions , 2002, Bioinform..

[18]  V. Fischetti,et al.  The importance of the location of antibody binding on the M6 protein for opsonization and phagocytosis of group A M6 streptococci , 1988, The Journal of experimental medicine.

[19]  R. Lancefield.  Current knowledge of type-specific M antigens of group A streptococci. , 1962, Journal of immunology.

[20]  J. Dale.  Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments. , 1999, Vaccine.